All Mergers and acquisitions articles – Page 3
-
Business
DowDupont names its three new separate businesses
Corteva Agriscience, Dow and DuPont will be what DowDuPont calls the three independent companies it will spin-off by June 2019
-
Business
BMS stimulates cancer drug hopes with giant collaboration
Immunooncology pioneer will pay up to $3.6bn in hope Nektar drug will help non-responders
-
Business
Sanofi enters M&A bonanza
French drugmaker strengthens rare diseases portfolio with blood disorder purchases
-
Business
Celgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
Business
Chemical industry roundup 2017
Economic and political pressure is encouraging industry to become more specialised as certain sectors consolidate
-
Business
Pharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
Business
DuPont and Sumitomo link up for seed treatments
Firms will collaborate to develop and commercialise seed-applied technologies
-
Business
Bayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
Business
China moves in on US shale gas
Alaska and West Virginia have welcomed investment from Chinese entities to develop US shale resources
-
Business
Valeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
Business
Generics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
Business
Novartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
Business
Lilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments
-
Business
Investor kills planned Huntsman–Clariant merger
Merger of equals abandoned after major Clariant investor said the deal would destroy stakeholder value
-
Business
BASF to buy Bayer seeds and herbicides
€5.9bn sale will help satisfy competition regulators’ worries over Bayer–Monsanto merger
-
Business
BASF to buy Solvay’s polyamide business
€1.6bn deal covers 2400 employees at sites in Europe, Asia and the Americas
-
Business
Teva to sell off women’s health businesses for $1.4bn
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
-
Business
Teva sells off contraceptive device in $1.1bn deal
CooperSurgical to acquire Paragard as Teva seeks to offload assets
-
Business
HB Fuller targets growth with trio of deals
Adhesives manufacturer will buy one Brazilian and two US glue companies
-
Business
Takeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses